Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer.

Abstract

BACKGROUND:

Organic cation transporter 6 (OCT6) encoded by solute carrier family 22 member 16 (SLC22A16) is involved in regulating cellular sensitivity and resistance to platinum derivatives. SLC22A16 has functional genetic variants but the association between these variants and the effectiveness of antitumor drugs remains unexplored.

PATIENTS AND METHODS:

This study retrospectively analyzed data from 160 patients with advanced non-small cell lung cancer treated with platinum-based combination chemotherapy for first-line chemotherapy between October 2010 and May 2018. We investigated the association between the genetic variant of SLC22A16 and clinical outcomes.

RESULTS:

Patients with the rs714368 GG genotype had a shorter progression-free survival than those with AA or AG. Gene polymorphism was not associated with adverse effects. The predictive effect of rs714368 was confirmed in multivariate analysis using a Cox proportional hazards model.

CONCLUSION:

A genetic variant of SLC22A16 is a potential predictive biomarker for response to platinum-based chemotherapy for non-small cell lung cancer.

• Authors: Akira Takeuchi, Tetsuya Oguri, Satoshi Fukuda, Kazuki Sone, Yusuke Kagawa, Takehiro Uemura, Osamu Takakuwa, Ken Maeno, Kensuke Fukumitsu, Yoshihiro Kanemitsu, Tomoko Tajiri, Hirotsugu Ohkubo, Masaya Takemura, Yutaka Ito, Akio Niimi
• Journal: Anticancer research (Anticancer Res) Vol. 40 Issue 8 Pg. 4245-4251 (Aug 2020) ISSN: 1791-7530 [Electronic] Greece
• PMID: 32727751 (Publication Type: Journal Article)
• Copyright: Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Biomarkers, Tumor
• Organic Cation Transport Proteins
• SLC22A16 protein, human
• Pemetrexed
• Bevacizumab
• Carboplatin
• Paclitaxel
• Cisplatin

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bevacizumab (administration & dosage)
• Biomarkers, Tumor (genetics)
• Carboplatin (administration & dosage)
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, pathology)
• Cisplatin (administration & dosage)
• Disease Progression
• Female
• Humans
• Lung Neoplasms (drug therapy, genetics, pathology)
• Male
• Middle Aged
• Organic Cation Transport Proteins (genetics)
• Paclitaxel (administration & dosage)
• Pemetrexed (administration & dosage)
• Polymorphism, Single Nucleotide
• Treatment Outcome